Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases |
| |
| Authors: | Hanane Rafi Nawal Kabbaj Mouna Salihoun Laila Amrani Mohamed Acharki Mouad Guedira Mhamed Nya Naima Amrani |
| |
| Affiliation: | 1. Division of Nuclear Medicine, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan;2. Department of Biomedical Imaging and Radiological Sciences, Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan;3. Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan;4. Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan;5. School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan;6. Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan;7. Department of Biotechnology, Asia University, Taichung, Taiwan;8. China Medical University Hospital, China Medical University, Taichung, Taiwan;1. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA;2. Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China;3. Lexington Veterans Affairs Medical Center, Lexington, KY, USA;1. Department of Internal Medicine, Hôpital de la Croix-Rousse, Lyon, France;2. University Claude Bernard-Lyon 1, Lyon, France;3. International Research Center on Infectiology (CIRI), Inserm U1111, Lyon, France;4. Department of Biochemistry, University of Lausanne, Epalinges, Switzerland;5. Assistance Publique — Hôpitaux de Paris, Hôpital Avicenne et Université Paris 13, Sorbonne Paris Cité, Bobigny, France;6. Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Necker Enfants malades University Hospital, APHP, IHU Imagine, Paris, France;7. Pasteur Institute, National Reference Center for Invasive Mycoses and Antifungals, Molecular Mycology Unit, Paris, France;8. CNRS URA3012, Paris, France;9. ECSTRA Team, Epidemiology and Biostatistics Sorbonne Paris Cité Research Centre UMR 1153, Inserm, Paris, France;10. Department of Internal Medicine, CHU Nantes, Nantes, France;1. Division of Nutritional Science, Graduate School of Human Health Science, University of Nagasaki, Siebold, Nagasaki, 851-2195, Japan;2. Food Science and Nutrition, Human Life Science and Environmental Sciences, Nara Women''s University, Nara, 630-8506, Japan;3. Department of Nutrition, Faculty of Nursing and Nutrition, University of Nagasaki, Siebold, Nagasaki, 851-2195, Japan;4. Department of Pathology and Laboratory Medicine, Tokushima University Graduate School, Tokushima, 770-8503, Japan |
| |
| Abstract: | Background and study aimsHepatic steatosis seems to be frequently found histopathologically in chronic hepatitis C virus (HCV)-infected patients. The aim of this study is to determine the influence of steatosis on HCV disease severity (fibrosis) and to evaluate its impact on sustained virological response (SVR) to antiviral therapy.Patients and methodsFrom April 2008 to April 2010, 148 consecutive adults (87 females (59%) and 61 males (41%); mean age: 55.2 years) with HCV admitted for liver biopsy were included in this retrospective study. At least one element of metabolic syndrome was identified in all cases: Obesity (n = 44), hyperlipidaemia (n = 40), hypertension (n = 29) and diabetes (n = 21). Liver fibrosis was classified according to the Metavir score and hepatic steatosis described as following: S0: absent; S1: minimal (<30%); S2: moderate (30–60%); and S3: severe (>60%). Patients were divided into two groups: S0S1 group (absent or minimal steatosis) and S2S3 group (moderate to severe steatosis). Of the 148 patients, 53 were treated with pegylated interferon and ribavirin combination therapy.ResultsSteatosis was found in 40 patients (27%): S1 in 72.5%, S2 in 17.5% and S3 in 10% of cases. The distribution of patients according to the degree of fibrosis was as follows: in the S0S1 group, F1 = 12.4%, F2 = 36.5%, F3 = 21.1% and F4 = 21.1% and in the S2S3 group, F1 = 9%, F2 = 45.5%, F3 = 18.2% and F4 = 27.3%. There was no difference between the two groups regarding the degree of fibrosis (p ? 0.80). The rate of SVR was 64%: 63% in the S0S1 group and 75% in the S2S3 group. The difference was not statistically significant (p = 1).ConclusionSteatosis was found in 25% of cases. Liver steatosis in chronic hepatitis C is not a negative prognostic factor of response to combined antiviral therapy. These results must be confirmed by a large series of patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
